IDNs (HCA, CommonSpirit, Ascension, Kaiser Permanente, Sutter, Intermountain) span multiple hospitals, ambulatory sites, and post-acute facilities under common ownership. They centralize purchasing, formularies, and clinical pathways. IDNs combine hospitals, physician groups and other care sites under one system. They often centralize purchasing and value analysis, so selling to them requires system-level economic evidence. Large IDNs may contract directly with manufacturers instead of relying only on GPOs.

Why it matters

Selling into IDNs typically requires corporate-level value-analysis approval before site-level adoption. Contract wins at large IDNs can swing quarterly results materially.

Common pitfalls

•A common pitfall is underestimating the complexity of an IDN's internal approval processes, which often involves multiple stakeholders beyond clinical users.
•Companies often fail to recognize that IDN contracts may require specialized cybersecurity and data integration agreements distinct from standard device sales.
•Another mistake is neglecting the impact of an IDN's centralized formulary or preferred product lists on device adoption and market access.
•Ignoring the IDN's own quality management and risk management frameworks can lead to friction in product implementation and support.
•Many MedTech companies mistakenly believe that a single site-level approval within an IDN translates to network-wide adoption without further strategic engagement.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.